Navigation Links
Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/5/2012

SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview, including with regard to the company's recent resubmission of the new drug application for lorcaserin.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication of lorcaserin and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review, including the assignment of a PDUFA date, and approval is uncertain; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory review or approval; Arena's submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc. Robert E. Hoffman, Vice President, Finance and Chief Financial Officer 858.453.7200  

 Investor Contact: Russo Partners, LLCMedia Contact: Russo Partners, LLCCindy McGee, Vice PresidentDavid Schull, President cindy.mcgee@russopartnersllc.comdavid.schull@russopartnersllc.com619.213.6995858.717.2310 

 www.arenapharm.com

  


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
2. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
3. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
4. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
5. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
6. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
7. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
8. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
9. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
11. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- The global  anxiety disorders and depression treatment market  is expected ... of depression worldwide is anticipated to drive the market growth in the coming ... for antidepressants in the recent years. Continue Reading ... ... ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
(Date:1/21/2017)... Research and Markets has announced the ... Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type ... (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" report ... ... market segments, especially clinical lab testing, which has evolved as ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... The Masters of Science in Healthcare ... with decades of experience who remain current practitioners in the field. With the ... is a renewed demand for versatile, data-driven leadership.The American University’s MS in Healthcare ...
(Date:1/23/2017)... ... 23, 2017 , ... METTLER TOLEDO has announced the availability ... Simple PAT Tools . , Crystallization is a common step used ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving ... a woman’s life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, ... , Charlotte, who credits the inspiration of the book to her sister, Denise, wishes ...
(Date:1/23/2017)... ... January 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance ... those who may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery ... additional $25 free. Or, spend $200 and get $50 free. , “A lot of ...
Breaking Medicine News(10 mins):